Aswan Fadhl

Aswan Fadhl serves as a key procurement professional within the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health under the Department of Health and Human Services. Responsible for managing complex research and analytical instrument acquisitions, Fadhl supports NIDA’s mission to advance scientific understanding of substance use disorders through targeted contracting for high-precision laboratory technologies. Their portfolio centers on funding cutting-edge neurobiological and behavioral research tools, ensuring that federally funded studies have access to state-of-the-art analytical instrumentation critical to drug abuse research and translational science. Fadhl maintains consistent partnerships with leading academic research institutions, including The McLean Hospital Corporation, the University of Maryland Baltimore, the University of Miami, the University of Pittsburgh, and the Icahn School of Medicine at Mount Sinai. These relationships reflect a pattern of awarding contracts to major research universities with established neuroscience and addiction research infrastructure, often for custom or specialized analytical equipment essential to laboratory-based studies. The working model emphasizes long-term scientific collaboration, with procurement aligned to institutional research capabilities and peer-reviewed project needs. Set-aside preferences are heavily skewed toward unrestricted competition, with 85.7% of awards issued without socioeconomic set-asides. While total small business set-asides account for 14.3%, there is no evidence of targeted 8(a), HUBZone, or SDVOSB preferences, indicating a procurement strategy prioritizing technical capability and scientific merit over socioeconomic criteria. Fadhl’s procurement activity is exclusively focused on NAICS 334516 — Analytical Laboratory Instrument Manufacturing — reflecting deep specialization in the acquisition of advanced scientific instruments such as mass spectrometers, neuroimaging systems, chromatography platforms, and biosensors. This technical domain requires rigorous evaluation of performance specifications, calibration standards, and compliance with FDA and CLIA guidelines, underscoring expertise in procuring high-complexity research equipment for biomedical laboratories.